首页> 美国卫生研究院文献>other >Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children
【2h】

Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children

机译:儿童呼吸药物的使用和非处方药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. Patients aged ≤18 years documented in the Bavarian Association of Statutory Health Insurance Physicians database (approx. 2 million children) between 2004 and 2008 were included in our study. Annual period prevalence rates (PPRs) per 10,000 children and the proportion of age- and indication-related off-label prescriptions were calculated and stratified by age and gender. Within the study period, highest PPRs were found for the fixed combination of clenbuterol/ambroxol (between 374–575 per 10,000 children) and the inhaled short acting beta-2-agonist salbutamol (between 378–527 per 10,000 children). Highest relative PPR increase was found for oral salbutamol (approx. 39-fold) whereas the most distinct decrease was found for oral long-acting beta-2-agonist clenbuterol (−97%). Compound classes most frequently involved in off-label prescribing were inhaled bronchodilative compounds (91,402; 37.3%) and oral beta-2-agonists (26,850; 22.5%). The highest absolute number of off-label prescriptions were found for inhaled salbutamol (n = 67,084; 42.0%) and oral clenbuterol/ambroxol (fixed combination, n = 18,897; 20.7%). Off-label prescribing due to indication was of much greater relevance than age-related off-label use. Most frequently, bronchodilative compounds were used off-label to treat respiratory tract infections. Highest off-label prescription rates were found in the youngest patients without relevant gender-related differences. Off-label prescribing of respiratory drugs is common especially in young children. Bronchodilative drugs were most frequently used off-label for treating acute bronchitis or upper respiratory tract infections underlining the essential need for a more rational prescribing in this area.
机译:呼吸道药物广泛用于儿童中,用于治疗标记和非标记适应症,但只有一些数据可用于量化标记外使用情况。因此,我们旨在分析与年龄和适应症相关的标签外使用,重点分析药物的利用和呼吸道药物的标签外处方。 2004年至2008年间,巴伐利亚州法定健康保险医师数据库记录的年龄≤18岁的患者(约200万儿童)被纳入我们的研究。每10,000名儿童的年流行率(PPR)以及与年龄和适应症相关的标签外处方所占的比例均按年龄和性别进行了分层。在研究期内,克仑特罗/氨溴索(每10,000名儿童介于374至575之间)和吸入的短效β-2-激动剂沙丁胺醇(每10,000名儿童介于378至527之间)的固定PPR最高。口服沙丁胺醇的相对PPR升高最高(约39倍),而口服长效β-2-激动剂克仑特罗的降低幅度最大(-97%)。标记外处方中最常涉及的化合物类别是吸入的支气管扩张性化合物(91,402; 37.3%)和口服β-2-激动剂(26,850; 22.5%)。吸入的沙丁胺醇(n = 67,084; 42.0%)和口服克仑特罗/氨溴索(固定组合,n = 18,897; 20.7%)的非处方处方绝对最高。与适应症相关的非处方药的使用,与适应症有关的非处方药的相关性要大得多。最经常地,支气管扩张性化合物被非标签地用于治疗呼吸道感染。在没有相关性别差异的最年轻患者中发现标签外处方率最高。呼吸道药物的标签外处方很普遍,尤其是在幼儿中。支气管扩张药物最常用于治疗急性支气管炎或上呼吸道感染的非处方药物,突显了该领域更合理处方的必要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号